Ensuring sustainable antiretroviral provision during economic crises

AIDS

Volumn 24, Issue 3, 2010, Pages 341-343

  Mills, Edward J ^a,b   Ford, Nathan ^c   Nabiryo, Christine ^b   Cooper, Curtis ^d   Montaner, Julio ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b THE AIDS SUPPORT ORGANIZATION   (Uganda)

^c Medecins Sans Frontiers ^*  (South Africa)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; DRUG MANUFACTURE; ECONOMIC ASPECT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; NOTE; PRIORITY JOURNAL; SCALE UP; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUDGETS; DECISION MAKING; FINANCIAL SUPPORT; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC;

EID: 75649084541     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283357e0f     Document Type: Note

References (22)

1. Souteyrand Y,Akwara P,Warner Smith M, Beusenberg M, Jashi M, Hayashi C, et al. Scaling up access to antiretroviral therapy (ART) in low-and middle-income countries: global and regional progress in 2008 [abstract #WELBD105]. In: 5th IAS Conference on HIV Pathogenesis Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa.
2. Zwillich T. Obama administration may flat-line funding for PEPFAR. Lancet 2009; 373:1325.
3. Mugyenyi P. Flat-line funding for PEPFAR: a recipe for chaos. Lancet 2009; 372:292.
4. Goosby E. Letter to PEPFAR Country Ambassadors focuses on transition to country ownership, technical assistance. http:// sciencespeaks.wordpress.com/ 2009/09/11/goosby-letter-to-pepfar-country-ambassadors-focuses-on-transition-to- country-ownership-technical-assistance/. [Accessed 27 October 2009]
5. Roehr B. HIV clinics are halting enrolment of new patients as funding stalls, MSF warns. BMJ 2009; 339:b2966.
6. Wasswa H. Uganda runs out of antiretroviral drugs after shortfall in aid. BMJ 2009; 339:b3255.
7. El-Khatib Z, Richter M. (ARVS) free state? The moratorium's threat to patients' adherence and the development of drug-resistant HIV. S Afr Med J 2009; 99:412.
8. Ndlovu N. Funds running out for ARVs. South Africa Mail and Guardian; 17 April 2009. http://www.mg.co.za/article/2009-04-08-funds-running-out-for-arvs.
9. Ravishankar N, Gubbins P, Cooley RJ, Leach-Kemon K, Mi-chaud CM, Jamison DT, Murray CJ. Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet 2009; 373:2113-2124.
10. Denny CC, Emanuel EJ. US health aid beyond PEPFAR: the mother & child campaign. JAMA 2008; 300:2048-2051.
11. Foundation for the Advancement of International Medical Education and Research. International Medical Education Directory; 2008. http://imed.ecfmg. org/search.asp.
12. Bärnighausen T, Bloom D, Humair S. Human resources for treating HIV/AIDS: needs, capacities, and gaps. AIDS Patient Care STDs 2007; 21:799-812.
13. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678-688.
14. Bärnighausen T, Bloom D. 'Conditional scholarships' for HIV/ AIDS health workers: educating and retaining the workforce to provide antiretroviral treatment in sub-Saharan Africa. Soc Sci Med 2009; 68:544-551.
15. Mullan F, Frehywot S. Nonphysician clinicians in 47 sub-Saharan African countries. Lancet 2007; 370:2158-2163.
16. Piot P, Kazatchkine M, Dybul M, Lob-Levyt J. AIDS: lessons learnt and myths dispelled. Lancet 2009; 374:260-263.
17. Manabe YC, Jacob ST, Thomas D, Quinn TC, Ronald A, Coutinho A, et al. Resurrecting the triple threat: academic social responsibility in the context of global health research. Clin Infect Dis 2009; 48:1420-1422.
18. Whitworth JA, Kokwaro G, Kinyanjui S, Snewin VA, Tanner M, Walport M, Sewankambo N. Strengthening capacity for health research in Africa. Lancet 2008; 372:1590-1593.
19. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
20. Kasirye R, Levin J, Munderi P, Okell L, Walker S, Mugisha A, Grosskurth H. Epidemiology of malaria in HIV infected Ugandan patients on antiretroviral therapy (ART): a prospective cohort study [abstract #TUPDB104]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa.
21. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536
22. Report of the inquiry of the All Party Parliamentary Group on AIDS into long-term access to HIV medicines in the developing world. http://www. aidsportal.org/repos/APPGTimebomb091. pdf.